Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-16T19:02:04.951Z Has data issue: false hasContentIssue false

Dietary diacylglycerol oil has no effect on hypertriacylglycerolaemia in lipoprotein lipase-deficient cats

Published online by Cambridge University Press:  28 April 2009

Craig A. Datz*
Affiliation:
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO65211, USA
Robert C. Backus
Affiliation:
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO65211, USA
Kevin L. Fritsche
Affiliation:
Division of Animal Sciences and Department of Nutritional Sciences, University of Missouri, Columbia, MO65211, USA
*
*Corresponding author: Dr Craig A. Datz, fax +1 573 884 7563, email datzc@missouri.edu
Rights & Permissions [Opens in a new window]

Abstract

A commercially available vegetable oil containing a high concentration (87 %, w/w) of diacylglycerol (DAG) has been investigated in humans and animals for potential beneficial effects in reducing serum TAG concentrations in fasting and postprandial states. Effects of DAG oil as a sole dietary fat source (25 % metabolisable energy) were evaluated in a feline model of hypertriacylglycerolaemia. Eleven adult (1·5 (sem 0·1) years) male cats deficient of lipoprotein lipase (LPL) catalytic activity from a heritable point mutation of the LPL gene were acclimatised to a semi-purified diet containing TAG oil for 21 d. After assignment into two groups, pair-matched by serum TAG concentrations (range 6·1–31·6 mmol/l), the cats were fed the diet with either TAG or DAG oil for 8 d. The dietary fat source was crossed-over and presented for 8 d more. Non-fasting serum concentrations of TAG, cholesterol and NEFA were measured on days 6–8 and days 14–16. Dietary fat source (DAG v. TAG) did not significantly affect food intake (491 (sem 16) v. 486 (sem 14) kJ/kg0·67), body weight or serum concentrations (mmol/l) of TAG (37·1 (sem 4·5) v. 33·9 (sem 3·4)), cholesterol (4·8 (sem 0·3) v. 4·8 (sem 0·2)) and NEFA (1·4 (sem 0·2) v. 1·4 (sem 0·2)). The results show that for a feeding trial of 8 d, DAG oil was well accepted and tolerated by cats but did not reduce hypertriacylglycerolaemia resulting from a deficiency of LPL catalytic activity.

Type
Full Papers
Copyright
Copyright © The Authors 2009

Diacylglycerol (DAG) is a natural component of vegetable oils, ranging from 1·0 % (w/w) in soyabean oil to 9·5 % in cottonseed oil(Reference D'Alonzo, Kozarek and Wade1, Reference Abdel-Nabey, Shehata and Ragab2). An edible oil rich in DAG (>80 %, w/w) has been synthesised by the reverse reaction of 1,3-specific lipase on vegetable oils such as soyabean and rapeseed which yields 1,3-DAG and 1,2 (2,3)-DAG in a ratio of 7:3 at equilibrium(Reference Watanabe, Shimizu and Sugiura3, Reference Takase4). DAG oil has been shown in human and animal studies to reduce fasting concentrations and postprandial elevations in serum TAG concentrations, increase energy expenditure and fat utilisation, reduce body fat accumulation and enhance weight loss(Reference Takase4Reference Yanai, Tomono and Ito7). The mechanism underlying these effects is hypothesised to be due to the unique molecular structure of DAG oil instead of the fatty acid composition. Unlike dietary TAG, which undergoes hydrolysis by gastric and pancreatic lipases to 2-monoacylglycerol (2-MAG) and NEFA, 1,3-DAG is hydrolysed to 1(3)-MAG and NEFA. The 1(3)-isoform has less affinity for acyl-CoA:monoacylglycerol acyltransferase, the main enzymic pathway involved in re-esterification of TAG in enterocytes, which leads to decreased synthesis of chylomicrons, increased release of NEFA into the portal circulation, and increased β-oxidation in hepatocytes(Reference Tada5).

In human studies, substitution of dietary DAG oil for TAG oil has been shown to reduce hypertriacylglycerolaemia resulting from various lipid disorders(Reference Yamamoto, Asakawa and Tokunaga8Reference Yamamoto, Takeshita and Tokimitsu13). Case studies in patients with severe hypertriacylglycerolaemia due to deficiencies of lipoprotein lipase (LPL) or apo C-II have reported lower serum TAG concentrations with DAG oil compared with TAG oil(Reference Yamamoto, Asakawa and Tokunaga14, Reference Yanai, Tada and Yoshida15). Based on these observations, we hypothesised that substitution of DAG oil for dietary fat in an animal model of LPL deficiency would reduce serum TAG concentrations. The assumption is that fatty acids derived from DAG would be less utilised in synthesis of circulating lipoproteins (chylomicrons, VLDL) than those derived from TAG. However, other human studies using DAG oil have found no effect on hypertriacylglycerolaemia(Reference Nagao, Watanabe and Goto16Reference Li, Xu and Takase18).

The animals used in the present study were adult domestic cats with LPL deficiency due to a mis-sense mutation in an exon of the LPL gene that leads to a substitution of arginine for glycine at residue 412(Reference Ginzinger, Lewis and Ma19). Cats homozygous with this mutation are globally devoid of LPL catalytic activity yet survive to adulthood and are able to reproduce(Reference Ginzinger, Clee and Dallongeville20Reference Kanchuk, Backus and Calvert23). The phenotype in these cats is similar to that of familial LPL deficiency in humans, which is a rare autosomal recessive disorder affecting an estimated one in one million of the population(Reference Brunzell, Deeb, Scriver, Beaudet and Sly24). Both LPL-deficient humans and cats have marked hypertriacylglycerolaemia, with reported serum TAG concentrations of 22–325 mmol/l in humans and 2–135 mmol/l in cats (normal fasting values: humans < 1·7; cats < 0·5). Because these cats are otherwise healthy when maintained on low-fat diets, they have the potential to serve as a unique model for evaluation of the effects of DAG oil on hypertriacylglycerolaemia resulting from LPL deficiency.

Experimental methods

Animals

Twelve specific pathogen-free domestic shorthair male cats aged 1·5 (sem 0·1) years, body weight (BW) 4·6 (sem 0·2) kg were obtained from and individually housed at the Feline Nutrition and Pet Care Center (University of California, Davis, CA, USA). Daily exercise and socialisation were provided in a group setting. Each cat was determined to be homozygous for the Gly412Arg LPL mutation by PCR-based mismatch analysis(Reference Ginzinger, Lewis and Ma19). Cats were given fresh food and water each morning, and remaining food from the previous day was collected and frozen for later DM determination. Diets and water were offered for ad libitum consumption. Food intakes, BW, faecal quality and general health observations were recorded daily. Body condition scores were assigned weekly according to a nine-point integer system in which 5 is ideal, 1 is leanest and 9 is the heaviest possible body condition(Reference Laflamme25).

Test oils

The evaluated DAG-rich oil was a commercially available product (Enova® oil; Kao Health and Nutrition LLC, Itasca, IL, USA). A TAG oil was prepared by mixing rapeseed oil, soyabean oil (Crisco® Pure Rapeseed and Crisco® Pure Vegetable Oil; J. M. Smucker Company, Orrville, OH, USA) and safflower-seed oil (LouAna Pure Safflower Oil; Ventura Foods, Brea, CA, USA) so that the fatty acid profile was similar to that of the DAG oil (Table 1). The fatty acid compositions of the TAG and DAG oils were analysed by extraction-methylation and GC(Reference Sukhija and Palmquist26).

Table 1 Acylglycerol and fatty acid compositions of the test oils

DAG, diacylglycerol.

* Analysed at Agricultural Experiment Station Chemical Laboratories, University of Missouri, Columbia, MO, USA.

As measured from lipid extracts followed by methylation and GC analyses as described in Experimental methods (n 3).

Diets

Two semi-purified diets were formulated to meet or exceed the recommended nutrient allowances for maintenance of adult cats(27). The diets differed only in oil source (Table 2). Diets were mixed and extruded through a meat grinder die (Hobart M-802, Hobart 4812, 1 cm die; Troy, OH, USA) to form pellets. The diets were stored frozen and thawed immediately before use.

Table 2 Diet composition (g/kg, as-fed basis) and macronutrient content*

DAG, diacylglycerol; ME, metabolisable energy.

* Calculated assuming protein, carbohydrate, and fat contain 16·7, 16·7 and 37·7 MJ/kg, respectively.

Dyets, Inc. (Bethlehem, PA, USA).

Supro 661 (Dyets, Inc., Bethlehem, PA, USA).

§ Enova® oil (Kao Health and Nutrition LLC, Itasca, IL, USA).

Crisco® Pure Rapeseed and Crisco® Pure Vegetable Oil (J. M. Smucker Co., Orrville, OH, USA), LouAna Pure Safflower Oil (Ventura Foods LLC, Brea, CA, USA).

NRC Cat Salt Mix (Dyets, Inc., Bethlehem, PA, USA) provided (g/kg diet): calcium phosphate tribasic, 570; potassium phosphate, 250; sodium chloride, 35; potassium chloride, 80; magnesium oxide, 19; manganous carbonate, 0·35; ferric citrate, 13; zinc carbonate, 2·8; cupric carbonate, 0·35; potassium iodate, 0·02; sodium selenite, 0·01; chromium potassium sulfate, 0·55; sucrose, 28·92.

** NRC Cat Vitamin Mixture (Dyets, Inc., Bethlehem, PA, USA) provided (g/kg diet): thiamin HCl, 0·7; riboflavin, 0·5; pyridoxine HCl, 0·6; niacin, 4·5; calcium pantothenate, 0·7; folic acid, 0·09; biotin, 0·01; vitamin B12 (0·1 %), 2·2; vitamin A palmitate (500 000 U/g), 1·3; vitamin D3 (400 000 U/g), 0·15; vitamin E acetate (500 U/g), 10·0; menadione sodium bisulfite, 0·02; myo-inositol, 20; sucrose, 959·23.

†† Choline chloride (Dyets, Inc., Bethlehem, PA, USA).

‡‡ VEVODAR Crude Arachidonic Oil (DSM Food Specialties, Delft, the Netherlands).

§§ Sigma Chemical Co. (St Louis, MO, USA).

Design

Two identical dietary cross-over studies were conducted approximately 6 months apart. For each study, six cats were gradually adapted from the standard colony diet, a commercial dry-type extruded diet (34 % metabolisable energy from fat, Whiskas® for kittens; Mars, Brentwood, TN, USA) to the semi-purified TAG diet for 21 d. At 2 d before the start of the study, a non-fasting 1 ml blood sample was collected from each cat by jugular venepuncture and submitted to a commercial laboratory (IDEXX, West Sacramento, CA, USA) for determination of serum TAG concentration. Cats were pair-matched based on serum TAG concentrations (range 6·1–31·6 mmol/l) and assigned to two groups of three cats each so that the range in serum TAG concentrations was similar between the groups. One group continued to receive the TAG diet after the adaptation period while the other group was switched to the DAG diet. After 8 d, the diets were crossed-over and presented for 8 d more with no washout period. The 8 d test period was selected to allow sufficient time for lipoprotein turnover(Reference Ginzinger, Clee and Dallongeville20).

Samples and analyses

Non-fasting blood samples were collected by jugular venepuncture from each cat on days 6–8 and again on days 14–16. The samples were allowed to clot, centrifuged at about 1200 g for 10 min, and serum separated and frozen at − 20°C for later analysis.

Serum TAG

A commercial enzymic-colorimetric kit (Infinity™; Thermo Electron, Pittsburgh, PA, USA) that measures glycerol after hydrolysis of acylglycerol was used to determine serum TAG concentrations. Due to the unusually high triacylglycerolaemia, serum was diluted from 1:5 to 1:15 with normal saline (0·9 % NaCl) so that assayed TAG concentrations were in the linear range of the test kit.

Serum cholesterol

Serum turbidity even after serial dilutions precluded use of colorimetric kits for cholesterol determinations. Cholesterol was determined in an organic-phase extract of serum by HPLC(Reference Webb, Lengle and Izzo28) with minor modifications. For each assay, 50 μl serum was mixed with 2 ml alcoholic potassium hydroxide solution (56·1 g potassium hydroxide in 1 litre ethanol) in a loosely capped glass tube and incubated in a 75°C water-bath for 30 min. After cooling, 2 ml deionised water was added and mixed. The tube was agitated with 5 ml hexanes for 15 min in a horizontal position then centrifuged at 200 g for 5 min. A 3 ml sample of hexanes (upper layer) was dried under N2 gas at 40°C. The residue was dissolved in 0·85 ml isopropanol and 50 μl reconstitute was injected onto an HPLC column (Microsorb 100-5 C18, 250 × 4·6 mm; Varian, Lake Forest, CA, USA). Cholesterol was eluted with an isocratic mobile phase (1:1 acetonitrile–isopropanol, 1·0 ml/min) in a peak monitored at 205 nm approximately 8·5 min after injection.

Serum NEFA

A commercial enzymic-colorimetric kit (Wako Diagnostics, Richmond, VA, USA) was used to determine serum NEFA concentration. Before analysis, samples were centrifuged at 13 000 g for 10 min at 4°C. The infranatant fraction (serum separated from the lipid layer) was used in the assay to avoid interference from sample turbidity.

Diet samples

The food intake of each cat was determined from the daily difference in DM mass of food offered and food remaining. For this, frozen ( − 15°C) samples of presented diet and uneaten diet samples were collected each day. Samples were dried in a convection oven at 110°C for 48 h and weighed to determine the DM. Each batch of diet was assayed for fatty acid composition by extraction-methylation and GC(Reference Sukhija and Palmquist26).

Calculations and statistical analysis

Results are expressed as means with their standard errors. Paired t tests and one-way repeated-measures ANOVA with Bonferroni adjustment for multiple comparisons were used to evaluate the effect of diet type and diet presentation sequence on mean serum concentrations of TAG, cholesterol and NEFA. The relationship between food intake and serum biochemical variables was evaluated by calculating Pearson correlation coefficients. Differences were considered significant at P < 0·05. Statistical analysis was performed with SPSS (version 16.0; SPSS Inc., Chicago, IL, USA) and SigmaStat (version 3.5; Systat Inc., San Jose, CA, USA).

The care and housing of the cats and the experimental protocol were approved by the Institutional Animal Care and Use Committee of the University of California, Davis, CA, USA. All institutional, state and federal guidelines were followed during the study.

Results

One cat was found to have normal serum TAG concentrations (pooled mean 0·52 (sem 0·17) mmol/l). Repeat analysis for occurrence of the Gly412Arg mutation in this cat revealed normal LPL alleles. Therefore, all observations from this cat were excluded from further analysis.

Body weights and general health

All cats accepted the semi-purified diet during the acclimatision period and the study periods. BW and body condition scores were maintained throughout the trial. Soft stool but not diarrhoea was noted in three cats on nine occasions; six while eating the DAG diet and three while eating the TAG diet.

Serum TAG, cholesterol and NEFA

Serum TAG concentrations varied by more than 400 % among the cats (Fig. 1). In contrast, within each cat, serum TAG concentrations were substantially less variable. The mean CV (sd/mean × 100) of TAG concentrations within cats during the TAG diet periods was only 23 ± 20 % and during the DAG diet periods was only 19 ± 13 %.

Fig. 1 Serum TAG concentration in lipoprotein lipase-deficient cats given diets with diacylglycerol (DAG) and TAG vegetable oils as the fat sources. Each symbol and connecting lines indicate observations common to each cat.

There was no significant effect of sampling day on serum TAG, cholesterol and NEFA concentrations. Therefore, mean concentrations were determined for each dietary period for each cat and these means were used for evaluation of the effect of diet. Serum TAG concentrations were not significantly different when cats received the TAG diet compared with the DAG diet (P = 0·47) (Table 3). The diets had no significant effect on serum cholesterol and NEFA concentrations (P = 0·81, 0·62). The order of diet presentation had no significant effect on serum TAG, cholesterol and NEFA concentrations (Table 4).

Table 3 Serum TAG, cholesterol and NEFA concentrations in lipoprotein lipase-deficient cats when given diets with TAG or diacylglycerol (DAG) vegetable oils as fat sources

(Mean values with their standard errors for eleven cats)

Table 4 Serum concentrations of TAG, cholesterol and NEFA by diet sequence (six cats for diacylglycerol (DAG)/TAG column; five cats for TAG/DAG column)

(Mean values with their standard errors)

To evaluate the effect of amount of food intake on the serum measurements, the significance of correlations between food intake and serum concentrations of TAG, cholesterol and NEFA were determined. For this analysis, food intake was calculated as the mean daily DM intake over the 8 d period of diet presentation and corresponding serum concentrations were calculated as the means of TAG, cholesterol and NEFA from the three sampling days of each diet period. No significant correlations were found between food intake and serum concentrations of TAG, cholesterol and NEFA when either diet was fed (P>0·33).

Discussion

The semi-purified diets presently used contained either TAG or DAG oil as the sole fat source. The diets were well accepted by all cats as indicated by food intake observations. Intake of the diets on a metabolisable energy basis (Table 5) was higher than the reported requirement for lean cats at maintenance, 418·4 kJ/kg BW0·67(27). The DAG oil appeared well tolerated because BW, faecal quality and overall health when the DAG oil diet was presented were not different from observations when the TAG oil diet was presented. Based on these findings, we conclude that DAG oil is palatable for cats and is suitable for inclusion in a complete and balanced feline diet. Long-term feeding studies of DAG-enriched diets are needed to verify nutritional adequacy.

Table 5 Daily food intakes by diet and intakes normalised to metabolic body weight (BW)

(Mean values with their standard errors for eleven cats)

DAG, diacylglycerol.

* DM basis (per d).

Metabolisable energy, metabolic body weight basis (per d).

There is normally a wide variation in circulating TAG concentrations among homozygous LPL-deficient cats(Reference Ginzinger, Clee and Dallongeville20, Reference Kanchuk, Backus and Calvert23, Reference Veltri, Backus and Rogers29). This was confirmed by a more than 400 % range in serum TAG concentrations observed in the present study (Fig. 1). Because of the great between-individual variance, we elected to evaluate dietary treatment effects with a cross-over design and balance grouping for order of diet presentation by preliminary serum TAG concentrations. We observed that TAG concentrations were relatively stable within individuals even with sampling during ad libitum food intake. The stability in serum TAG concentrations probably reflects inconsequential impact of meals. Serum TAG is very slowly cleared in LPL-deficient cats(Reference Ginzinger, Clee and Dallongeville20), and TAG formed from the eleven to twenty meals per d typically consumed by cats(Reference Kane, Morris and Rogers30) probably contributes only a small fraction to the large pool of circulating TAG in LPL-deficient cats.

The cause for the large and consistent between-individual differences in serum TAG concentrations was not apparent. Serum TAG concentrations did not appear to reflect the amount of dietary fat consumed because the TAG concentrations were not significantly correlated with food intake. Activity of secondary mechanisms of TAG removal, perhaps involving hepatic lipase(Reference Demacker, Hijmans and Stalenhoef31), endothelial lipase(Reference Jaye and Krawiec32) or receptor-mediated transport(Reference Goudriaan, Espirito Santo and Voshol33), might underlie individual differences in serum TAG concentrations. These secondary mechanisms would appear especially effective in cats. Normalisation of triacylglycerolaemia in LPL deficiency after an oral fat challenge occurs more rapidly in cats (about 24 h)(Reference Ginzinger, Clee and Dallongeville20) than in humans (>40 h)(Reference Sprecher, Knauer and Black34).

We did not identify lower mean serum TAG concentrations in cats receiving the DAG diet compared with the TAG diet (Table 3). Therefore, our observations do not support the hypothesis that substitution of DAG oil as the sole source of dietary fat reduces serum TAG concentrations in this animal model. Although dietary DAG oil did not appear to be harmful in LPL-deficient cats, we did not find evidence of a benefit. It is noteworthy that our findings may not reflect responses of humans with LPL deficiency. Metabolism of DAG oil in cats may importantly deviate from that in humans.

A simple explanation for a lacking effect of DAG oil is that the ability of the oil to lower TAG may depend on the presence of functional LPL. Chylomicrons generated by the metabolism and absorption of DAG were reported to be more efficiently hydrolysed compared with those generated by dietary TAG oil in mice(Reference Yasunaga, Saito and Ahzng35). The LPL-deficient cats studied are devoid of LPL catalytic activity and do not produce an immunoreactive mutant protein(Reference Ginzinger, Lewis and Ma19). Other enzymes such as hepatic lipase and endothelial lipase may be principally responsible for chylomicron hydrolysis in LPL-deficient cats(Reference Veltri, Backus and Rogers29). Activities of these enzymes in removal of chylomicrons may be little affected by dietary fat source. A non-catalytic function of LPL may mediate the beneficial effect of dietary DAG oil. Dietary fat substitution with DAG oil was recently reported to reduce triacylglycerolaemia in a human patient with apo C-II deficiency(Reference Yanai, Tada and Yoshida15). Though not catalytically active, LPL was present in the patient. However, a beneficial effect of DAG oil in reducing triacylglycerolaemia was reported in a patient with no functional LPL mass or LPL catalytic activity(Reference Yamamoto, Asakawa and Tokunaga14).

Cats have many similarities to humans with respect to lipid metabolism including abundant and separable HDL2 and HDL3 subfractions(Reference Demacker, Hijmans and Stalenhoef31, Reference Chapman36). Serum cholesterol was presently measured as an indicator of the potential effects of DAG oil on cholesterol-rich lipoproteins. Serum cholesterol concentrations were not significantly affected by the dietary fat source (Table 3). This observation is consistent with other human and animal studies in that total cholesterol concentrations remain unchanged by dietary DAG oil, with few exceptions in which serum cholesterol was lowered(Reference Taguchi, Watanabe and Onizawa37Reference Fujii, Allen and Nestel40).

Although DAG oil fatty acids are reputedly absorbed principally as NEFA(Reference Rudkowska, Roynette and Demonty6), the jugular venous serum NEFA concentrations presently observed were unaffected by dietary DAG (Table 3). This observation is also consistent with previous reports(Reference Tada, Shoji and Takeshita11, Reference Taguchi, Watanabe and Onizawa37, Reference Yasunaga, Glinsmann and Seo41). However, in some studies serum NEFA concentrations were higher with DAG oil compared with TAG oil(Reference Kamphuis, Mela and Westerterp-Plantenga42, Reference Sugimoto, Kimura and Fukuda43). LPL-deficient compared with normal cats tend to have higher NEFA concentrations when food is continuously present, while in normal cats NEFA levels are higher when food is withheld(Reference Veltri, Backus and Rogers29). In the present study, diets were not withheld at any time and NEFA fluctuated within a narrow range of concentrations.

The study was designed to evaluate short-term effects of DAG oil on serum TAG concentrations. Food was continuously presented, and there was no attempt to collect fasting or postprandial blood samples. In a previous report of LPL-deficient cats, plasma TAG concentrations after an oral fat load increased 10-fold (from 0·97 to 9·36 mmol/l) and peaked at 7 h compared with a 2-fold increase and 3 h peak in normal cats(Reference Ginzinger, Clee and Dallongeville20). Further studies are needed to determine if DAG oil has the potential to reduce postprandial TAG concentrations or increase the rate of clearance in LPL-deficient cats.

In summary, the present results show that cats voluntarily consume and tolerate diets prepared with DAG oil at 10 % DM weight and 25 % metabolisable energy for short time periods. The present results also show that the marked hypertriacylglycerolaemia seen with LPL deficiency is unchanged by substitution of TAG with DAG oil. Our finding of a lack of effect of DAG oil on triacylglycerolaemia is not without precedent. Lowering of triacylglycerolaemia in normal animals is not consistently reported. Nevertheless, the lack of effect on triacylglycerolaemia that we observed may be unique to the LPL deficiency model studied, or it may be a consequence of a unique attribute of the fatty acid metabolism of cats. Future studies of dietary applications of DAG oil in LPL-deficient and normal cats are warranted. These should include evaluation of postprandial effects on lipid profiles and long-term studies on DAG effects on energy metabolism, obesity prevention and treatment, and disorders such as insulin resistance and diabetes mellitus, which are observed in cats.

Acknowledgements

The authors thank the following individuals: Debbie Bee, who cared for the study cats and collected the samples; Ying Liu, who assisted with assays and statistical analysis; Lada Micheas and Suhwon Lee, who assisted with statistical analysis; and Dr Jon Ramsey, who oversaw the study on-site. The entire project was supported by a Resident Research grant from Nestlé Purina PetCare (St Louis, MO, USA).

C. A. D. designed the study, carried out most of the experimental procedures and prepared the manuscript. R. C. B. assisted with study design, experimental procedures and the manuscript. He served as the mentor for C. A. D.'s graduate school training. K. L. F. assisted with experimental procedures and provided laboratory support.

The grant award was numbered 0013672 and the title was ‘Effects of diacylglycerol oil in cats affected with inherited hyperchylomicronemia’.

There are no conflicts of interest for any of the authors or individuals acknowledged as assisting in the present study.

References

1D'Alonzo, RP, Kozarek, WJ & Wade, RL (1982) Glyceride composition of processed fats and oils as determined by glass capillary gas chromatography. J Am Oil Chem Soc 59, 292295.CrossRefGoogle Scholar
2Abdel-Nabey, AA, Shehata, AAY & Ragab, MH (1992) Glycerides of cottonseed oils from Egyptian and other varieties. Riv Ital Sostanze Grasse 69, 443447.Google Scholar
3Watanabe, T, Shimizu, M, Sugiura, M, et al. (2003) Optimization of reaction conditions for the production of DAG using immobilized 1,3-regiospecific lipase lipozyme RM IM. J Am Oil Chem Soc 80, 12011207.CrossRefGoogle Scholar
4Takase, H (2007) Metabolism of diacylglycerol in humans. Asia Pac J Clin Nutr 16, Suppl. 1, 398403.Google ScholarPubMed
5Tada, N (2004) Physiological actions of diacylglycerol outcome. Curr Opin Clin Nutr Metab Care 7, 145149.CrossRefGoogle ScholarPubMed
6Rudkowska, I, Roynette, CE, Demonty, I, et al. (2005) Diacylglycerol: efficacy and mechanism of action of an anti-obesity agent. Obes Res 13, 18641876.CrossRefGoogle ScholarPubMed
7Yanai, H, Tomono, Y, Ito, K, et al. (2007) Diacylglycerol oil for the metabolic syndrome. Nutr J 6, 43.CrossRefGoogle ScholarPubMed
8Yamamoto, K, Asakawa, H, Tokunaga, K, et al. (2001) Long-term ingestion of dietary diacylglycerol lowers serum triacylglycerol in type II diabetic patients with hypertriglyceridemia. J Nutr 131, 32043207.CrossRefGoogle ScholarPubMed
9Teramoto, T, Watanabe, H, Ito, K, et al. (2004) Significant effects of diacylglycerol on body fat and lipid metabolism in patients on hemodialysis. Clin Nutr 3, 11221126.CrossRefGoogle Scholar
10Takase, H, Shoji, K, Hase, T, et al. (2005) Effect of diacylglycerol on postprandial lipid metabolism in non-diabetic subjects with and without insulin resistance. Atherosclerosis 180, 197204.CrossRefGoogle ScholarPubMed
11Tada, N, Shoji, K, Takeshita, M, et al. (2005) Effects of diacylglycerol ingestion on postprandial hyperlipidemia in diabetes. Clin Chim Acta 353, 8794.CrossRefGoogle ScholarPubMed
12Yamamoto, K, Tomonobu, K, Asakawa, H, et al. (2006) Diet therapy with diacylglycerol oil delays the progression of renal failure in type 2 diabetic patients with nephropathy. Diabetes Care 29, 417419.CrossRefGoogle ScholarPubMed
13Yamamoto, K, Takeshita, M, Tokimitsu, I, et al. (2006) Diacylglycerol oil ingestion in type 2 diabetic patients with hypertriglyceridemia. Nutrition 22, 2329.CrossRefGoogle ScholarPubMed
14Yamamoto, K, Asakawa, H, Tokunaga, K, et al. (2005) Effects of diacylglycerol administration on serum triacylglycerol in a patient homozygous for complete lipoprotein lipase deletion. Metabolism 54, 6771.CrossRefGoogle Scholar
15Yanai, H, Tada, N, Yoshida, H, et al. (2007) Diacylglycerol oil for apolipoprotein C-II deficiency. Q J Med 100, 247249.CrossRefGoogle ScholarPubMed
16Nagao, T, Watanabe, H, Goto, N, et al. (2000) Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial. J Nutr 130, 792797.CrossRefGoogle Scholar
17Kawashima, H, Takase, H, Yasunaga, K, et al. (2008) One-year ad libitum consumption of diacylglycerol oil as part of a regular diet results in modest weight loss in comparison with consumption of a triacylglycerol control oil in overweight Japanese subjects. J Am Diet Assoc 108, 5766.CrossRefGoogle ScholarPubMed
18Li, D, Xu, T, Takase, H, et al. (2008) Diacylglycerol-induced improvement of whole-body insulin sensitivity in type 2 diabetes mellitus: a long-term randomized, double-blind controlled study. Clin Nutr 27, 203211.CrossRefGoogle ScholarPubMed
19Ginzinger, DG, Lewis, MES, Ma, Y, et al. (1996) A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats. J Clin Invest 97, 12571266.CrossRefGoogle Scholar
20Ginzinger, DG, Clee, SM, Dallongeville, J, et al. (1999) Lipid and lipoprotein analysis of cats with lipoprotein lipase deficiency. Eur J Clin Invest 29, 1726.CrossRefGoogle ScholarPubMed
21Backus, RC, Ginzinger, DG, Ashbourne Excoffon, KJD, et al. (2001) Maternal expression of functional lipoprotein lipase and effects on body fat mass and body condition scores of mature cats with lipoprotein lipase deficiency. Am J Vet Res 62, 264269.CrossRefGoogle ScholarPubMed
22Reginato, CF, Backus, RC & Rogers, QR (2002) Improved growth of lipoprotein lipase deficient kittens by feeding a low-fat, highly digestible diet. J Nutr Biochem 13, 149156.CrossRefGoogle ScholarPubMed
23Kanchuk, ML, Backus, RC, Calvert, CC, et al. (2003) Weight gain in gonadectomized normal and lipoprotein lipase-deficient male domestic cats results from increased food intake and not decreased energy expenditure. J Nutr 133, 18661874.CrossRefGoogle Scholar
24Brunzell, JD & Deeb, SS (2001) Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency. In The Metabolic and Molecular Bases of Inherited Disease, 8th ed., pp. 27892800 [Scriver, CR, Beaudet, AL and Sly, WS et al. , editors]. New York: McGraw-Hill.Google Scholar
25Laflamme, D (1997) Development and validation of a body condition score system for cats: a clinical tool. Feline Pract 25, 1318.Google Scholar
26Sukhija, PS & Palmquist, DL (1988) Rapid method for determination of total fatty acid content and composition of feedstuffs and feces. J Agric Food Chem 36, 12021206.CrossRefGoogle Scholar
27National Research Council (2006) Nutrient Requirements of Cats and Dogs, pp. 366. Washington, DC: National Academies Press.Google Scholar
28Webb, LE, Lengle, E, Izzo, R, et al. (1982) Micromethod for lipid-chromatographic determination of cholesterol in lipemic sera. Clin Chem 28, 17691772.CrossRefGoogle ScholarPubMed
29Veltri, BC, Backus, RC, Rogers, QR, et al. (2006) Adipose fatty acid composition and rate of incorporation of α-linolenic acid differ between normal and lipoprotein lipase-deficient cats. J Nutr 136, 29802986.CrossRefGoogle ScholarPubMed
30Kane, E, Morris, JG & Rogers, QR (1981) Acceptability and digestibility by adult cats of diets made with various sources and levels of fat. J Anim Sci 53, 15161523.CrossRefGoogle ScholarPubMed
31Demacker, PNM, Hijmans, AGM, Stalenhoef, AFH, et al. (1988) Studies on the function of hepatic lipase in the cat after immunological blockade of the enzyme in vivo. Atherosclerosis 69, 173183.CrossRefGoogle ScholarPubMed
32Jaye, M & Krawiec, J (2004) Endothelial lipase and HDL metabolism. Curr Opin Lipidol 15, 183189.CrossRefGoogle ScholarPubMed
33Goudriaan, JR, Espirito Santo, SMS, Voshol, PJ, et al. (2004) The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J Lipid Res 45, 14751481.CrossRefGoogle Scholar
34Sprecher, DL, Knauer, SL, Black, DM, et al. (1991) Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families. J Clin Invest 88, 985994.CrossRefGoogle ScholarPubMed
35Yasunaga, K, Saito, S, Ahzng, YL, et al. (2007) Effects of triacylglycerol and diacylglycerol oils on blood clearance, tissue uptake, and hepatic apolipoprotein B secretion in mice. J Lipid Res 48, 11081121.Google ScholarPubMed
36Chapman, MJ (1980) Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 21, 789853.CrossRefGoogle ScholarPubMed
37Taguchi, H, Watanabe, H, Onizawa, K, et al. (2000) Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans. J Am Coll Nutr 19, 789796.CrossRefGoogle Scholar
38Murase, T, Mizuno, T, Omachi, T, et al. (2001) Dietary diacylglycerol suppresses high fat and high sucrose diet-induced body fat accumulation in C57BL/6J mice. J Lipid Res 42, 372378.CrossRefGoogle ScholarPubMed
39Umeda, T, Bauer, JE & Otsuji, K (2006) Weight loss effect of dietary diacylglycerol in obese dogs. J Anim Physiol Anim Nutr (Berl) 90, 208215.CrossRefGoogle ScholarPubMed
40Fujii, A, Allen, TJ & Nestel, PJ (2007) A 1,3 diacylglycerol-rich oil induces less atherosclerosis and lowers plasma cholesterol in diabetic apoE-deficient mice. Atherosclerosis 193, 5561.CrossRefGoogle Scholar
41Yasunaga, K, Glinsmann, WH, Seo, Y, et al. (2004) Safety aspects regarding the consumption of high-dose dietary diacylglycerol oil in men and women in a double-blind controlled trial in comparison with consumption of a triacylglycerol control oil. Food Chem Toxicol 42, 14191429.CrossRefGoogle Scholar
42Kamphuis, MMJW, Mela, DJ & Westerterp-Plantenga, MS (2003) Diacylglycerols affect substrate oxidation and appetite in humans. Am J Clin Nutr 77, 11331139.CrossRefGoogle ScholarPubMed
43Sugimoto, T, Kimura, T, Fukuda, H, et al. (2003) Comparisons of glucose and lipid metabolism in rats fed diacylglycerol and triacylglycerol oils. J Nutr Sci Vitaminol (Tokyo) 49, 4755.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Acylglycerol and fatty acid compositions of the test oils

Figure 1

Table 2 Diet composition (g/kg, as-fed basis) and macronutrient content*

Figure 2

Fig. 1 Serum TAG concentration in lipoprotein lipase-deficient cats given diets with diacylglycerol (DAG) and TAG vegetable oils as the fat sources. Each symbol and connecting lines indicate observations common to each cat.

Figure 3

Table 3 Serum TAG, cholesterol and NEFA concentrations in lipoprotein lipase-deficient cats when given diets with TAG or diacylglycerol (DAG) vegetable oils as fat sources(Mean values with their standard errors for eleven cats)

Figure 4

Table 4 Serum concentrations of TAG, cholesterol and NEFA by diet sequence (six cats for diacylglycerol (DAG)/TAG column; five cats for TAG/DAG column)(Mean values with their standard errors)

Figure 5

Table 5 Daily food intakes by diet and intakes normalised to metabolic body weight (BW)(Mean values with their standard errors for eleven cats)